FDA Antibiotics Incentives List Goes Beyond GAIN Act
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The agency’s proposed rule on qualifying pathogens is longer than the initial legislative list, but industry still awaits regulations on the law’s exclusivity bonus, which are only achieved through a separate qualified disease product designation.